Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant: View Uses, Side Effects and Medicines

Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant

INFORMATION ABOUT HUMAN PAPILLOMAVIRUS 9-VALENT (TYPES 6,11,16,18,31,33,45,52 AND 58) VACCINE, RECOMBINANT

Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant Uses

Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant is used in the treatment of genital warts and HPV-associated cancers.

How Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant works

Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant stimulates the body to produce antibodies that, in future encounters with human papillomavirus (strains causing cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers), bind to the virus and prevent it from infecting cells.

Common side effects of Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common

Injection site reactions (pain, swelling, redness), Headache, Dizziness, Nausea, Tiredness, Fever

CONTENT DETAILS

Last updated

07 May 2025 | 06:46 PM (UTC)

We provide you with authentic, trustworthy and revelant information

Read our editorial policy

Medicine brands for Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant

Expert advice for Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant

Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant does not remove the need for screening for cervical, vulvar, vaginal, anal, and certain head and neck cancers, such as throat and back of mouth cancers; women should still get routine cervical cancer screening.
Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant does not protect the person getting Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant from a disease that is caused by other types of HPV, other viruses or bacteria.
It does not treat HPV infection.
It may not fully protect each person who gets it.
Inform your doctor if you might have had an allergic reaction to a previous dose of Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant.
Tell your doctor if you take medicines that affect the immune system.

Frequently asked questions for Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant

Q. What is Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant?

Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant is a vaccine designed to protect against certain strains of the human papillomavirus (HPV), which can lead to cervical, vulvar, vaginal, and anal cancers, as well as genital warts. It boosts the immune system to recognize and fight these HPV strains and provides significant protection against the virus.

Q. Who should get Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant?

Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant is recommended for both males and females starting at the age of 9 up to age 45. It is particularly important for individuals before they become sexually active to receive the vaccine for optimal protection.

Q. How is Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant administered?

Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant is typically administered in either two or three doses, depending on the age and health status of the individual. For individuals aged 9 through 14, it is usually given in two doses, with the second dose administered 6 to 12 months after the first. For those aged 15 through 45, or those with certain health conditions, it is given in three doses: the second dose 1 to 2 months after the first, and the third dose 6 months after the first. Follow the recommended schedule for maximum protection.

Q. What are the common side effects of Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant?

The most common side effects of Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant pain, swelling, or redness at the injection site, as well as headache, fever, nausea, and tiredness. These reactions are usually mild and temporary.

Q. Is Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant safe?

Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant is considered safe and effective for the prevention of HPV-related diseases. Extensive clinical trials have demonstrated its safety profile, and it has been approved by regulatory agencies worldwide.

Q. Are there any contraindications or precautions for Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant?

Individuals with a history of severe allergic reactions to any component of the vaccine should avoid Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52 and 58) Vaccine, Recombinant. Additionally, vaccination may be delayed or deferred in individuals who are currently ill or have certain medical conditions. It is essential to consult with a healthcare provider to assess individual suitability for vaccination.